BR0316332A - Composto pirazólico, composição farmacêutica e agente analgésico contendo o mesmo, processo para sua preparação e seu uso e pacote comercial - Google Patents

Composto pirazólico, composição farmacêutica e agente analgésico contendo o mesmo, processo para sua preparação e seu uso e pacote comercial

Info

Publication number
BR0316332A
BR0316332A BR0316332-6A BR0316332A BR0316332A BR 0316332 A BR0316332 A BR 0316332A BR 0316332 A BR0316332 A BR 0316332A BR 0316332 A BR0316332 A BR 0316332A
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical composition
agent containing
analgesic agent
containing same
Prior art date
Application number
BR0316332-6A
Other languages
English (en)
Inventor
Fumiyuki Shirai
Hidenori Azami
Natsuko Kayakiri
Kazuo Okumura
Katsuya Nakamura
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002953019A external-priority patent/AU2002953019A0/en
Priority claimed from AU2002953602A external-priority patent/AU2002953602A0/en
Priority claimed from AU2003902015A external-priority patent/AU2003902015A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BR0316332A publication Critical patent/BR0316332A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO PIRAZóLICO, COMPOSIçãO FARMACêUTICA E AGENTE ANALGéSICO CONTENDO O MESMO, PROCESSO PARA SUA PREPARAçãO E SEU USO E PACOTE COMERCIAL". Composto pirazólico de fórmula (I): onde: R¬ 1¬ é hidrogênio ou alquila inferior; R¬ 2¬ é alquila inferior, etc.; R¬ 3¬ é alcoxi inferior, etc.; R¬ 4¬ é hidroxi, etc.; X é O, S, etc.; Z é alquileno inferior ou alquenileno inferior; e m é O ou 1; ou seus sais que são úteis como medicamento.
BR0316332-6A 2002-12-02 2003-11-14 Composto pirazólico, composição farmacêutica e agente analgésico contendo o mesmo, processo para sua preparação e seu uso e pacote comercial BR0316332A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2002953019A AU2002953019A0 (en) 2002-12-02 2002-12-02 Azole derivatives
AU2002953602A AU2002953602A0 (en) 2002-12-30 2002-12-30 New compounds
AU2003902015A AU2003902015A0 (en) 2003-04-29 2003-04-29 Azole derivatives
PCT/JP2003/014489 WO2004050632A1 (en) 2002-12-02 2003-11-14 Pyrazole derivatives useful as cox-i inhibitors

Publications (1)

Publication Number Publication Date
BR0316332A true BR0316332A (pt) 2005-09-27

Family

ID=32474716

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316332-6A BR0316332A (pt) 2002-12-02 2003-11-14 Composto pirazólico, composição farmacêutica e agente analgésico contendo o mesmo, processo para sua preparação e seu uso e pacote comercial

Country Status (16)

Country Link
US (2) US7183306B2 (pt)
EP (1) EP1567503B1 (pt)
JP (1) JP4419078B2 (pt)
KR (1) KR20050083761A (pt)
AR (1) AR042273A1 (pt)
AT (1) ATE538097T1 (pt)
BR (1) BR0316332A (pt)
CA (1) CA2505945A1 (pt)
ES (1) ES2379076T3 (pt)
HK (1) HK1087102A1 (pt)
MX (1) MXPA05005742A (pt)
NO (1) NO20053215L (pt)
NZ (1) NZ540515A (pt)
PL (1) PL377778A1 (pt)
TW (1) TW200410942A (pt)
WO (1) WO2004050632A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517870A (ja) * 2001-01-02 2004-06-17 藤沢薬品工業株式会社 シクロオキシゲナーゼ阻害剤
ES2379076T3 (es) 2002-12-02 2012-04-20 Astellas Pharma Inc. Derivados de pirazol útiles como inhibidores de COX-I
AU2004209495A1 (en) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
US20050075323A1 (en) * 2003-03-05 2005-04-07 Pfizer Inc Beta3 adrenergic receptor agonists and uses thereof
US20060079566A1 (en) * 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
DE602005016082D1 (de) * 2004-02-20 2009-10-01 Astrazeneca Ab 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
TW200613297A (en) * 2004-07-01 2006-05-01 Daiichi Seiyaku Co Pyrazole derivatives
RU2007108297A (ru) * 2004-08-06 2008-09-20 Дайити Фармасьютикал Ко., Лтд. (JP) Антитромбоцитарное средство и способ его получения
JP2008526887A (ja) * 2005-01-10 2008-07-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なヘテロピロール類似体
FR2882365B1 (fr) * 2005-02-21 2007-09-07 Sanofi Aventis Sa Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique
GB0514739D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
GB0516661D0 (en) * 2005-08-13 2005-09-21 Astrazeneca Ab Therapeutic agents
WO2007111323A1 (ja) 2006-03-27 2007-10-04 Toray Industries, Inc. ウレイド誘導体およびその医薬用途
EP2070908A4 (en) 2006-09-07 2011-08-10 Univ Okayama Nat Univ Corp COMPOUND HAVING A BENZAMIDE SKELETER AND A SELECTIVE CYCLOOXYGENASE INHIBITORY ACTIVITY (COX-1)
MX2009006214A (es) * 2006-12-18 2009-06-22 7Tm Pharma As Moduladores del receptor cb1.
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
WO2008105383A1 (ja) * 2007-02-26 2008-09-04 Toray Industries, Inc. ピラゾール誘導体およびその医薬用途
JPWO2008114859A1 (ja) * 2007-03-22 2010-07-08 アステラス製薬株式会社 ピラゾール誘導体を含有する医薬組成物
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
WO2009099670A2 (en) * 2008-02-08 2009-08-13 Nektar Therapeutics Al, Corporation Oligomer-cannabinoid conjugates
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
EP2289868B1 (en) 2008-06-25 2014-08-13 Daiichi Sankyo Company, Limited Carboxylic acid compound
US20120046356A1 (en) * 2008-10-02 2012-02-23 Cambrex Karlskoga Ab New process for preparing diketones and medicaments
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
US20120108823A1 (en) 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
DE102011055815A1 (de) * 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
WO2017190086A1 (en) 2016-04-29 2017-11-02 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
EP3497084B1 (en) 2016-08-15 2021-01-13 Bayer CropScience Aktiengesellschaft Process for the preparation of 3-amino-1-(2,6-disubstituted-phenyl)pyrazoles
CA3036195A1 (en) * 2016-09-07 2018-03-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
CN115611790A (zh) * 2022-10-31 2023-01-17 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种甲硫基甲基苯基醚的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164381A (en) * 1986-05-29 1992-11-17 Ortho Pharmaceutical Corporation Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US5051518A (en) * 1987-05-29 1991-09-24 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US5298521A (en) * 1993-08-30 1994-03-29 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use
AU3815495A (en) 1994-11-08 1996-05-31 Eisai Co. Ltd. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
ES2136018B1 (es) 1997-06-17 2000-07-01 Menarini Lab Compuestos inhibidores selectivos de la ciclooxigenasa-i y su utilizacion como analgesicos, antiinflamatorios y antiartriticos.
JP2002516909A (ja) * 1998-06-05 2002-06-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換１−（４−アミノフェニル）ピラゾール及び抗炎症剤としてのそれらの使用
WO2000018741A2 (en) * 1998-09-30 2000-04-06 Fujisawa Pharmaceutical Co., Ltd. Pyrazole compounds as cox-2 inhibitors
AU4308300A (en) 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
PT1104759E (pt) 1999-12-03 2004-01-30 Pfizer Prod Inc Compostos heteroaril-fenil-pirazole como agentes anti-inflamatorios e analgesicos
US6600052B1 (en) * 2000-04-25 2003-07-29 Pharmacia Corporation Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
JP2004517870A (ja) 2001-01-02 2004-06-17 藤沢薬品工業株式会社 シクロオキシゲナーゼ阻害剤
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
US20030162824A1 (en) * 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
ATE422201T1 (de) * 2002-04-05 2009-02-15 Cadila Healthcare Ltd 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
ES2379076T3 (es) 2002-12-02 2012-04-20 Astellas Pharma Inc. Derivados de pirazol útiles como inhibidores de COX-I
CN100421632C (zh) 2005-02-01 2008-10-01 金磊 人工心脏瓣膜成形环

Also Published As

Publication number Publication date
MXPA05005742A (es) 2005-08-16
JP2006514095A (ja) 2006-04-27
NO20053215D0 (no) 2005-06-30
NZ540515A (en) 2008-01-31
EP1567503B1 (en) 2011-12-21
KR20050083761A (ko) 2005-08-26
CA2505945A1 (en) 2004-06-17
AR042273A1 (es) 2005-06-15
PL377778A1 (pl) 2006-02-20
WO2004050632A1 (en) 2004-06-17
JP4419078B2 (ja) 2010-02-24
US7183306B2 (en) 2007-02-27
US20070112037A1 (en) 2007-05-17
TW200410942A (en) 2004-07-01
US20040116475A1 (en) 2004-06-17
HK1087102A1 (en) 2006-10-06
NO20053215L (no) 2005-09-01
ES2379076T3 (es) 2012-04-20
EP1567503A1 (en) 2005-08-31
ATE538097T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
BR0316332A (pt) Composto pirazólico, composição farmacêutica e agente analgésico contendo o mesmo, processo para sua preparação e seu uso e pacote comercial
BR0111667A (pt) Novos compostos
BR0108678A (pt) Novos compostos
BRPI0015254C1 (pt) compostos derivados de carbamoiloxialquil-azólio, seu uso, bem como composição farmacêutica compreendendo os mesmos.
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
BRPI9914741A (pt) n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas.
BR0316609A (pt) Sinomenina e compostos de sinomenina, sìntese e uso
BR0307606A (pt) Derivados de piperazinila, piperidinila e morfolinila como inibidores de histona desacetilase
BRPI0415587A (pt) composto de 2-ciano-pirrolidina-carboxamida, método para produzì-lo, medicamento, composição farmacêutica, inibidor de dpp-iv contendo tal composto, método para tratamento e/ou prevenção de niddm, uso do composto para tratamento e/ou prevenção de niddm e embalagem comercial da composição farmacêutica contendo tal composto
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BRPI0419305B8 (pt) compostos inibidores de p38, composições farmacêuticas compreendendo os mesmos e usos dos referidos compostos na preparação de medicamentos
BRPI0212726B8 (pt) compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos
BR0015605A (pt) Composição e uso
BRPI0307267B8 (pt) uso de compostos inibidores de beta-lactamases e composições farmacêuticas para terapia antibacteriana
BR0307575A (pt) Derivados de sulfonila como inibidores de histona desacetilase
BR0315665A (pt) Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento
BR0209064A (pt) Hidroxamatos de alquila tricìclicos, sua preparaçãoe seu uso como inibidores de proliferação de células
BR0016395A (pt) Derivados de adamantano
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
BRPI0512986A (pt) novos derivados de hidantoìna
BR0211863A (pt) 1-alquil ou 1-cicloalquiltriazolo[4,3a]quinazolin-5-onas como inibidores da fosfodiesterase
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.